

Add the following claims:

5. A method for transducing hematopoietic progenitor cells, comprising co-culturing human hematopoietic progenitor cells with isolated human mesenchymal stem cells, and transducing the human hematopoietic progenitor cells with exogenous genetic material in the presence of the isolated human mesenchymal stem cells.

REMARKS

In response to the Examiner's helpful suggestions and the rejections under 35 U.S.C. 112, Claim 1 has been cancelled and has been replaced with Claim 5.

Claims 1, 3, and 4 stand rejected under 35 U.S.C. 102(b) as being anticipated by Reese, et al.

Claims 1, 3, and 4 stand rejected under 35 U.S.C. 102(b) as being anticipated by Nolta, et al.

Claims 1-4 stand rejected under 35 U.S.C. 103 as being unpatentable over Reese, et al. in view of Gerson, et al.

Claims 1-4 stand rejected under 35 U.S.C. 103 as being unpatentable over Nolta, et al. in view of Gerson, et al.

These rejections are respectfully traversed.

The present invention, as defined broadly in Claim 5, is directed to a method for transducing hematopoietic progenitor cells. The method comprises co-culturing human hematopoietic progenitor cells with isolated human mesenchymal stem cells, and transducing the human hematopoietic progenitor cells with exogenous genetic material in the presence of the isolated human mesenchymal stem cells.